RxDoctor Payments Data

Nicholas Mwangi

Psychiatric/Mental Health · Fords, NJNPI 1851967525

Payments from drug & device makers

$992in general payments, 2019–2025

Across 61 payments — averaging $16.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$620
  • Teva Pharmaceuticals USA, Inc.$239
  • Otsuka America Pharmaceutical, Inc.$87
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$18
  • Supernus Pharmaceuticals, Inc.$14
  • Johnson & Johnson$13

What the payments were for

  • Food & beverage$78279%
  • Education$20921%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$992 in reported general payments places this provider in the 65th percentile of 1,212 psychiatric/mental health providers in New Jersey.

See all psychiatric/mental health providers in New Jersey

Medicare billing

Part B allowed, 2024
$276,367
Medicare patients
844
Services billed
2,480

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole15$11,116
Divalproex Sodium176$6,578
Aripiprazole65$4,910
Mirtazapine163$3,652
Atomoxetine Hcl20$3,213
Escitalopram Oxalate216$2,766
Duloxetine Hcl62$2,314
Sertraline Hcl149$1,899
Desvenlafaxine Succinate ErDesvenlafaxine Succinate40$1,880
Clozapine44$1,835
Quetiapine Fumarate145$1,660
Buspirone Hcl83$1,590
Risperidone67$1,143
Olanzapine52$916
Bupropion XlBupropion Hcl53$792

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$87$11,11615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,212 psychiatric/mental health providers in New Jersey.

Other psychiatric/mental health in Fords

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →